Longitudinal Plasma Protein Profiling Using Targeted Proteomics and Recombinant Protein Standards

Area of Science:

• Proteomics
• Biomarker Discovery
• Clinical Chemistry

Background:

• Multiplexed protein quantification is crucial for biomarker discovery and clinical diagnostics.
• Accurate and precise protein measurements are essential for reliable diagnostic assays.
• Targeted proteomics offers a potential alternative to traditional antibody-based methods.

Purpose of the Study:

• To establish a quantitative targeted proteomics method for multiplexed plasma protein analysis.
• To validate the method using isotope-labeled recombinant standards from the Human Protein Atlas.
• To assess the longitudinal variability of plasma proteins in a human cohort.

Main Methods:

• Development of a targeted proteomics assay for 21 FDA-classified drug targets and clinical biomarkers.
• Utilized isotope-labeled recombinant standards for accurate quantification.
• Longitudinal profiling of a human cohort with samples collected over one year at four time points.
• Benchmarking of targeted proteomics assays for APOA1 and APOB against antibody-based clinical assays.

Main Results:

• Established a multiplexed targeted proteomics assay for 21 plasma proteins.
• Demonstrated accurate and precise quantification using isotope-labeled standards.
• Observed high correlation between targeted proteomics and antibody-based assays for APOA1 and APOB.
• Provided insights into longitudinal plasma proteome variability within individuals.

Conclusions:

• Targeted proteomics with multiplexed analysis is an attractive alternative to antibody-based protein assays.
• The developed method enables accurate and precise quantification of clinically relevant plasma proteins.
• The study highlights the utility of targeted proteomics for longitudinal biomarker profiling.